Brief: US FDA Approves Leqembi® IQKLIK™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
29/08/2025 23:22
Aug 29 (Reuters) - BioArctic AB BIOAb.ST: US FDA APPROVES LEQEMBI® IQKLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION FOR MAINTENANCE DOSING FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE Source text: ID:nPreZJfx0a Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million